175 related articles for article (PubMed ID: 34761635)
1. Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?
Erdogan B; Kostek O; Bekir Hacioglu M; Gokyer A; Kucukarda A; Ozcan E; Gokmen I; Uzunoglu S; Cicin I
J BUON; 2021; 26(5):2196-2201. PubMed ID: 34761635
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of Systemic Inflammatory Biomarkers in Patients with Metastatic Renal Cell Carcinoma.
Nader Marta G; Isaacsson Velho P; Bonadio RRC; Nardo M; Faraj SF; de Azevedo Souza MCL; Muniz DQB; Bastos DA; Dzik C
Pathol Oncol Res; 2020 Oct; 26(4):2489-2497. PubMed ID: 32583330
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.
Kobayashi H; Okuma T; Oka H; Hirai T; Ohki T; Ikegami M; Sawada R; Shinoda Y; Akiyama T; Sato K; Abe S; Kawano H; Goto T; Tanaka S
Int J Clin Oncol; 2018 Apr; 23(2):368-374. PubMed ID: 29086877
[TBL] [Abstract][Full Text] [Related]
4. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
Topal A; Sayın S; Gokyer A; Kucukarda A; Kostek O; Bekir Hacıoglu M; Uzunoglu S; Erdogan B; Cicin I
J BUON; 2021; 26(4):1628-1634. PubMed ID: 34565028
[TBL] [Abstract][Full Text] [Related]
5. Persistence and compliance with pazopanib in patients with advanced renal cell carcinoma within a U.S. administrative claims database.
Hackshaw MD; Nagar SP; Parks DC; Miller LA
J Manag Care Spec Pharm; 2014 Jun; 20(6):603-10. PubMed ID: 24856598
[TBL] [Abstract][Full Text] [Related]
6. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial.
Sternberg CN; Davis ID; Mardiak J; Szczylik C; Lee E; Wagstaff J; Barrios CH; Salman P; Gladkov OA; Kavina A; Zarbá JJ; Chen M; McCann L; Pandite L; Roychowdhury DF; Hawkins RE
J Clin Oncol; 2010 Feb; 28(6):1061-8. PubMed ID: 20100962
[TBL] [Abstract][Full Text] [Related]
7. Prospective Translational Study Investigating Molecular PrEdictors of Resistance to First-Line PazopanIb in Metastatic reNal CEll Carcinoma (PIPELINE Study).
Sepe P; Martinetti A; Mennitto A; Verzoni E; Claps M; Raimondi A; Sottotetti E; Grassi P; Guadalupi V; Stellato M; Zattarin E; Di Maio M; Procopio G
Am J Clin Oncol; 2020 Sep; 43(9):621-627. PubMed ID: 32889831
[TBL] [Abstract][Full Text] [Related]
8. Possibility for Dose Optimization of Pazopanib from Its Plasma Concentration in Japanese Patients with Cancer.
Tanaka H; Hiraga H; Takekuma Y; Harabayashi T; Nagamori S; Endo M; Sugawara M
Biol Pharm Bull; 2020 May; 43(5):762-766. PubMed ID: 32115446
[TBL] [Abstract][Full Text] [Related]
9. Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma.
Aoyama T; Nakano K; Yuasa T; Sugiyama E; Okawa T; Ito K; Azuma K; Hashimoto K; Furutani R; Hiraide M; Kobayashi K; Suzuki K; Tomomatsu J; Tajima M; Sato H; Hama T; Takahashi S
Sci Rep; 2023 Feb; 13(1):2099. PubMed ID: 36746987
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: a Southern China Urology Cancer Consortium Trial.
Xie M; He CS; Huang JK; Lin QZ
Eur J Cancer; 2015 Mar; 51(5):595-603. PubMed ID: 25618828
[TBL] [Abstract][Full Text] [Related]
11. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
[TBL] [Abstract][Full Text] [Related]
12. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
Brotelle T; Bay JO
Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
[TBL] [Abstract][Full Text] [Related]
13. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials.
Tran HT; Liu Y; Zurita AJ; Lin Y; Baker-Neblett KL; Martin AM; Figlin RA; Hutson TE; Sternberg CN; Amado RG; Pandite LN; Heymach JV
Lancet Oncol; 2012 Aug; 13(8):827-37. PubMed ID: 22759480
[TBL] [Abstract][Full Text] [Related]
14. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Erman M; Biswas B; Danchaivijitr P; Chen L; Wong YF; Hashem T; Lim CS; Karabulut B; Chung HJ; Chikatapu C; Ingles S; Slimane K; Kanesvaran R
BMC Cancer; 2021 Sep; 21(1):1021. PubMed ID: 34521387
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib in metastatic soft tissue sarcomas: Testing the waters in developing world.
Bajpai J; Mullapally SK; Kapoor A; Ghosh J; Rekhi B
Indian J Cancer; 2021; 58(3):365-370. PubMed ID: 33753596
[TBL] [Abstract][Full Text] [Related]
16. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
[TBL] [Abstract][Full Text] [Related]
17. Pazopanib after sunitinib failure in patients with metastatic renal cell carcinoma.
Rautiola J; Utriainen T; Peltola K; Joensuu H; Bono P
Acta Oncol; 2014 Jan; 53(1):113-8. PubMed ID: 23721300
[TBL] [Abstract][Full Text] [Related]
18. Pazopanib as third line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile.
Pal SK; Hossain DM; Zhang Q; Frankel PH; Jones JO; Carmichael C; Ruel C; Lau C; Kortylewski M
J Urol; 2015 Apr; 193(4):1114-21. PubMed ID: 25286010
[TBL] [Abstract][Full Text] [Related]
19. Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection.
Tardy C; Puszkiel A; Boudou-Rouquette P; De Percin S; Alexandre J; Berge M; Ulmann G; Blanchet B; Batista R; Goldwasser F; Thomas Schoemann A
Cancer Chemother Pharmacol; 2024 Feb; 93(2):169-175. PubMed ID: 37620675
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Pazopanib on the Cardiovascular System.
Justice CN; Derbala MH; Baich TM; Kempton AN; Guo AS; Ho TH; Smith SA
J Cardiovasc Pharmacol Ther; 2018 Sep; 23(5):387-398. PubMed ID: 29706106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
